Roivant Sciences (ROIV) has drawn fresh attention after announcing a US$2.25b global settlement with Moderna that ends ongoing patent litigation, along with positive IMVT-1402 rheumatoid arthritis data and Breakthrough Therapy Designation for brepocitinib.

At a share price of US$31.43, Roivant Sciences has seen a 4.63% 7 day share price return and a 13.47% 90 day share price return. Its 1 year total shareholder return of 174.50% and 3 year total shareholder return of around 3.2x reflect recent share price performance around the settlement and clinical updates.

If Roivant’s recent catalysts have your attention, this could be a useful moment to broaden your watchlist with other high potential healthcare AI opportunities using the 41 healthcare AI stocks.

With Roivant Sciences now past a major legal overhang and trading at US$31.43 alongside an indicated discount to analyst targets and intrinsic value estimates, you have to ask: is this a fresh entry point, or is the market already banking on future growth?

Most Popular Narrative: 19.5% Undervalued

Roivant Sciences is trading at $31.43 against a widely followed fair value estimate of $39.04, which frames the current optimism around its recent catalysts.

The analysts have a consensus price target of $39.04 for Roivant Sciences based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $45.0, and the most bearish reporting a price target of just $31.5.

Want to see what sits behind that gap between Roivant’s current price and the narrative fair value? The story leans heavily on steep revenue expansion, a sharp swing in margins, and a rich future earnings multiple that turns today’s loss making profile into a very different earnings picture.

Result: Fair Value of $39.04 (UNDERVALUED)

However, there is still meaningful execution risk around Roivant Sciences’ crowded clinical calendar and competitive pressure that could challenge assumptions behind the 19.5% undervaluation narrative.

Next Steps

With Roivant Sciences sitting between clear risks and real upside, are you prepared to move past the headlines and test the numbers for yourself? To balance those concerns and potential rewards, start with the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Roivant Sciences?

If Roivant Sciences has sharpened your interest, do not stop there. Broaden your watchlist with focused ideas that match your risk tolerance and income goals.

• Target resilience by scanning for companies with robust finances using the solid balance sheet and fundamentals stocks screener (48 results).
• Hunt for mispriced opportunities by zeroing in on the 45 high quality undervalued stocks.
• Build a cash flow oriented portfolio by focusing on the 8 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.